Optimizing Sequencing in EGFR-Mutant Advanced NSCLC

Heather Wakelee, MD, and Helena Yu, MD, discuss how they approach patient selection for osimertinib monotherapy vs combination therapy in 2026.

Heather Wakelee, MD, and Helena Yu, MD, examine how FLAURA2 and emerging post-progression data inform sequencing decisions.

Heather Wakelee, MD, and Helena Yu, MD, discuss when chemotherapy rechallenge may be appropriate in EGFR-mutant NSCLC.

Heather Wakelee, MD, and Helena Yu, MD, discuss how TP53 and other co-mutations influence prognosis and sequencing decisions.

Heather Wakelee, MD, and Helena Yu, MD, discuss how ADCs are being incorporated into sequencing strategies after osimertinib.

Heather Wakelee, MD, and Helena Yu, MD, discuss how to plan long-term treatment sequencing from the time of diagnosis.

Heather Wakelee, MD, and Helena Yu, MD, discuss emerging biomarkers and key evidence gaps in EGFR-mutant NSCLC.